Unicycive Therapeutics has filed a base prospectus with the US Securities and Exchange Commission (SEC) for an offering of securities up to $150M. The filing allows the company to offer and sell debt securities, common stock, preferred stock, warrants, and units. This move provides Unicycive Therapeutics with flexibility to raise capital in the future as market conditions permit.

The base prospectus serves as a preliminary registration statement, detailing the types of securities that may be offered. Unicycive Therapeutics has not yet specified the exact timing, size, or terms of any particular offering. The securities may be sold from time to time in one or more transactions, which could include underwritten offerings, negotiated transactions, or direct sales to investors.

The filing indicates that the net proceeds from the offering will be used for general corporate purposes. These purposes may include working capital, capital expenditures, research and development activities, and potential acquisitions or strategic investments. The company retains the discretion to allocate the funds based on its operational needs and strategic priorities.

Unicycive Therapeutics specializes in the development of novel therapies for kidney diseases. The ability to access capital markets through this shelf registration supports the company's long-term financial strategy and pipeline development. The prospectus is available on the SEC's website, providing transparency to potential investors regarding the proposed securities offering.